Single-cell transcriptome analysis reveals onco-fetal reprogramming with implications for drug resistance and clinical outcome.

Onco-fetal (OF) cells are detected across multiple cancers, exhibit stem-like properties, and their high abundance predicts worse prognosis and increased drug resistance.

• Why it matters: Understanding onco-fetal reprogramming addresses a gap in knowledge about tumor progression and treatment failure, offering potential targets for improving clinical outcomes.
• What they did: Using a computational pipeline on single-cell transcriptomic data from fetal and tumor tissues across various cancers, the study identified OF cells and their core transcription factors, including PTMA, ATF5, TCF4, and FOS.
• The result: High OF cell abundance is linked to impaired B cell function, enhanced drug resistance, and cancer recurrence, suggesting OF cells as promising targets for precision oncology interventions.